The correlation between metabolic syndrome and neurocognitive and social cognitive performance of patients with schizophrenia.


Journal

Psychiatry research
ISSN: 1872-7123
Titre abrégé: Psychiatry Res
Pays: Ireland
ID NLM: 7911385

Informations de publication

Date de publication:
06 2020
Historique:
received: 19 02 2019
revised: 17 03 2020
accepted: 23 03 2020
pubmed: 26 4 2020
medline: 4 11 2020
entrez: 26 4 2020
Statut: ppublish

Résumé

Cognitive impairment is one of the core symptoms of schizophrenia, and patients with schizophrenia are at increased risk of metabolic syndrome (MS). However, the role of MS in cognitive impairment of schizophrenia is not established. This study investigated the correlation between neurocognitive, social cognitive performance and MS with schizophrenia. One hundred and fifty eight (158) schizophrenia patients were divided into 3 groups with ① normal metabolism, ② metabolic disorder (only meeting 1 or 2 MS criteria), and ③ metabolic syndrome (meeting 3 or more MS criteria). MATRICS Consensus Cognitive Battery)MCCB(and the Brief Psychiatric Rating Scale)BPRS(were used to evaluate cognitive performance and clinical symptoms. Blood samples were obtained to detect glucose and lipid metabolic levels. Overall MCCB and subscale T scores in the normal metabolism and metabolic disorder groups were better than in the MS group. After controlling for the confounding factors including age, sex, the usage of hypolipidemic and hypoglycemic drugs, and disease duration, metabolic deficits had effects on the symbol coding and spatial span scores. The results suggest that a defective metabolic state might play a role in neurocognitive performance of schizophrenia patients.

Identifiants

pubmed: 32334274
pii: S0165-1781(19)30444-5
doi: 10.1016/j.psychres.2020.112941
pii:
doi:

Substances chimiques

Hypoglycemic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112941

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest There is no conflict of interest in relation to this paper.

Auteurs

Shengyun Chen (S)

Psychiatry Department, the 3rd affiliated hospital, Sun Yat-sen University, Guangzhou, China.

Xiaowei Xia (X)

Psychiatry Department, the 3rd affiliated hospital, Sun Yat-sen University, Guangzhou, China.

Chao Deng (C)

School of Medicine, University of Wollongong, Wollongong, Australia; Antipsychotic Research Laboratory, Illawarra Health and Medical Research Institute, Wollongong, Australia.

Xiuhua Wu (X)

Psychiatry Department, the 3rd affiliated hospital, Sun Yat-sen University, Guangzhou, China.

Zili Han (Z)

Psychiatry Department, the 3rd affiliated hospital, Sun Yat-sen University, Guangzhou, China.

Jiong Tao (J)

Psychiatry Department, the 3rd affiliated hospital, Sun Yat-sen University, Guangzhou, China. Electronic address: taojiong@mail.sysu.edu.cn.

Xiaoli Wu (X)

Psychiatry Department, the 3rd affiliated hospital, Sun Yat-sen University, Guangzhou, China. Electronic address: xiaoliwu@mail.sysu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH